Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on June 21, 2019, regarding the results of its 2019 Annual Meeting of Stockholders held on that date. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol "COCP".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
Stockholders voted on three proposals at the Annual Meeting:
- Proposal 1 (Election of Directors): Stockholders elected six directors for a one-year term. All nominees received majority support, though significant broker non-votes (4,177,938) were recorded for each nominee. Votes withheld ranged from 10,821 to 1,168,822.
- Proposal 2 (Equity Plan Amendment): Stockholders approved an amendment to the 2015 Equity Incentive Plan to increase authorized shares by 2,294,762, bringing the total to 5,000,000 shares. The vote was split, with 12,298,019 votes for and 9,884,690 votes against.
- Proposal 3 (Auditor Ratification): Stockholders ratified the appointment of Weinberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2019. The vote was overwhelmingly in favor with 26,263,772 votes for and 70,392 votes against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on outlook, specific risks, contingencies, or unusual items. The document serves strictly as a disclosure of voting results.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to contextualize the voting percentages, as the filing lists raw vote counts.
- Note the significant number of broker non-votes (4,177,938) on the director election, which may indicate a large block of shares held in street name without voting instructions.
- Review the definitive proxy statement filed on April 30, 2019, for detailed biographies of the elected directors and the specific terms of the Equity Incentive Plan amendment.
- Confirm the impact of the approved equity plan amendment on potential future dilution, as the authorized share count increased to 5,000,000.